Drug Trial Radar · NCT06813924
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Feb 6, 2025
Primary completion
May 27, 2025
Study completion May 27, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.
Conditions
- Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
EtavopivatDrug
Participants will receive a daily dose of etavopivat orally.
DigoxinDrug
Participants will receive a single dose of digoxin orally.
PitavastatinDrug
Participants will receive a single dose of pitavastatin orally.
MetforminDrug
Participants will receive a single dose of metformin orally.
MidazolamDrug
Participants will receive a single dose of midazolam orally.
RosuvastatinDrug
Participants will receive a single dose of rosuvastatin orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after digoxin administration
- AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after digoxin administration
- Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 after rosuvastatin administration
- AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 after rosuvastatin administration
- Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady stateTime frame: Day 1 after midazolam administration
- AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady stateTime frame: Day 1 after midazolam administration
- Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after pitavastatin administration
- AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after pitavastatin administration
- Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after metformin administration
- AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after metformin administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON-Salt Lake City
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.